ClinicalTrials.gg
Not yet recruitingNCT06444789dBM-DEVUpdated Aug 27, 2024

AI-PROGNOSIS - Digital Biomarkers Development Study (dBM-DEV)

An observational study in Parkinson Disease, sponsored by University Hospital, Toulouse. Not yet recruiting at 4 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by University Hospital, Toulouse · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
90
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Parkinson Disease by University Hospital, Toulouse — 7 open to participants now, 7 under way, 1 of them phase 3. Parkinson Disease · University Hospital, Toulouse.

Started
2024
with 4 others
Observational
8 of 33
2 open now
Registered
28th of 33
by date

Among the 33 studies in Parkinson Disease by University Hospital, Toulouse, this one is one of 5 that started in 2024, is one of 8 observational ones, and was the 28th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

7 of the 33 studies in Parkinson Disease by University Hospital, Toulouse are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Parkinson Disease by University Hospital, Toulouse, or all of them as a file.
02

Study summary

dBM-dev study is a multicentre low-intervention research study which concerns REM sleep behaviour disorder (RBD) who is the best predictor for neurodegenerative diseases including Parkinson's disease (PD). RBD can only be confirmed by polysomnography, which is a cumbersome procedure. The main objective of this study is to identify a novel, robust dBM for the detection of RBD using smartwatch-based recordings of passive data.The study is conducted step-wise on two subsequent cohorts referred to as the development cohort and the confirmation cohort.

Read the detailed description

The development cohort comprises 30 patients with RBD and 30 matched controls on sex and age with patients RBD.

The confirmation cohort comprises 30 patients with PD. Following a baseline visit comprising standard clinical evaluation and Parkinson questionnaires, participants will undergo daily-life dBM tracking over a duration of 4 weeks for development cohort and 3 months for confirmation cohort. Additionally, PD patients enrolled in the confirmation cohort will receive a polysomnography which permits to verificate if they have a RBD. The investigation is conducted in four European sites.

03

Conditions studied

  • Parkinson Disease

Keywords

  • REM sleep behaviour disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

1 group of persons with RBD

1 group of persons without RBD

1 group of persons with Parkinson disease

Eligibility criteria

Inclusion Criteria for development cohort:

Group of RBD patients

  • Diagnosis of RBD (confirmed by polysomnography)
  • Able to use a compatible smartphone with the study app
  • Having a care partner with whom they share their bedroom at night

Group of Healthy matched controls:

  • Healthy volunteers age and sex matched to the enrolled RBD patients.
  • Able to use a compatible smartphone with the study app
  • No history of RBD.

Inclusion Criteria for confirmation cohort

  • Clinical confirmed diagnosis of PD
  • RBD Screening Questionnaire score : 3 - 12 points
  • Absence of dementia
  • Able to use a compatible smartphone with the study app
  • Having a care partner with whom they share their bedroom at night

Exclusion Criteria for all cohorts:

Inability to consent for study procedures as judged by the investigator. Lacking motivation to participate in study procedures as judged by the investigator.

Lack of social security.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Development cohort of patients with known RBD

    Detection of RBD signs by using the connected smartwach during 4 weeks

    Device: connected smartwatch

  • Development cohort of matched controls = people who don't have RBD age and sex matched

    Detection of RBD signs by using the connected smartwach during 4 weeks

    Device: connected smartwatch

  • Confirmation cohort of parkinson disease patients = people who are supposed to have RBD

    Detection of RBD signs by using the connected smartwach during 3 months

    Device: connected smartwatch

Interventions

  • Deviceconnected smartwatch

    The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.

06

What researchers measure

Primary outcomes

  1. Incidence of nights in a confirmation cohort in which RBD episodes are indicated by a score (digital biomarker) derived from passive actigraphy and photoplethysmography data captured by a smartwatch

    the digital biomarker will be identified from passive actigraphy and photoplethysmography data of a separate development cohort

    Time frame: 4 weeks

Secondary outcomes

  1. correlation between a) and b)

    1. the incidence of daytime somnolence episodes per week indicated by a score (digital biomarker) derived from passive actigraphy and photoplethysmography data captured by a smartwatch. The digital biomarker will be identified from passive actigraphy and photoplethysmography data of a separate development cohort 2. the score of the Epworth Sleepiness Scale at baseline, measured by the Spearman correlation coefficient, in a confirmation cohort

    Time frame: 4 weeks for a) 3 months for b)

  2. Number of camera-based movement assessments acquired by each participant relative to the number of scheduled camera-based movement assessments.

    Time frame: 4 weeks (for development cohort) and 3 months (for confirmation cohort)

  3. Number of cognitive tasks completed by each participant relative to the number of scheduled cognitive tasks.

    Time frame: 4 weeks (for development cohort) and 3 months (for confirmation cohort)

07

Study locations

4 sites
  • Neurology Toulouse Hospital
    Toulouse, France
    • Amel DRIF · Contactamel.drif@inserm.fr
    • Margherita FABBRI · Principal investigator
    • Olivier RASCOL · Sub investigator
  • Klinik und Poliklinik für Neurologie of University Hospital (Regulatory autorization pending)
    Dresden, Germany
    • Björn FALKENBURGER · Contact
    • Björn FALKENBURGER · Principal investigator
  • Hospital Ruber Internacional
    Madrid, Spain
    • Monica KURTIS · Contact
    • Monica KURTIS · Principal investigator
  • King's college of London (Regulatory authorization pending)
    London, United Kingdom
    • Dhaval TRIVEDI · Contact
    • Dhaval TRIVEDI · Principal investigator
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Jul 2025, 9 months later.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 9 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
Jun 6, 2024
StartEst.
Sep 20, 2024
Primary completionEst.
Jul 15, 2025
CompletionEst.
Jul 15, 2025
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06444789
Collaborators
European Union, University Hospital Carl Gustav Carus, Aristotle University Of Thessaloniki
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Sep 20, 2024 (estimated)
Primary completion
Jul 15, 2025 (estimated)
Completion
Jul 15, 2025 (estimated)
Last update
Aug 27, 2024

Study contacts

Nadege ALGANS
Contact
algans.n@chu-toulouse.fr
33-561777204
Anna RIBYCKA
Contact
ribycka.a@chu-toulouse.fr
33-561778252
Margherita FABBRI
principal investigator · Toulouse Hospital
Björn FALKENBURGER
study chair · University Hospital Carl Gustav Carus of Dresden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion